Program objective

 

Identify at-risk patients for clinical trials or care.

The challenge

 

abstract graphic

In 2020, approximately 400,000 American baby boomers will have Alzheimer’s disease, according to the Alzheimer’s Association. By 2040, that number is expected to reach 10.3 million, greatly impacting the affected individuals, families, care providers and more.* 

The disease has no cure. And treatment options are limited. That’s why OptumLabs® has partnered with the Global CEO Initiative on Alzheimer’s Disease, and others, to explore ways to use our data to support Alzheimer’s and dementia research. 

Our role

 

Project INSIGHT is our collaborative effort to  develop predictive models to better identify  people earlier who are at risk of Alzheimer’s disease and dementia. The goal is to enable earlier testing of potential treatments and increase the chance of a cure. 

With our partners, we have developed predictive models using regression techniques and newer machine learning approaches. Current models can identify potential signals of dementia five to eight years earlier than the first diagnosis.   

Our goal is to continue to improve these results through a deep-learning approach to building predictive models.

OptumLabs’ robust data set can drive significant improvements in our understanding of Alzheimer’s, addressing unmet needs in research.

– Darshak Sanghavi, MD, Chief Medical Officer and SVP Translation, OptumLabs

Collaborators

 

Founders

  • Global CEO Initiative on Alzheimer's Disease
  • OptumLabs

Sponsors 

  • AstraZenica
  • Janssen
  • Optum
  • Roche

Research partners

  • University of Maryland: The Founding Campus
  • OptumLabs

Expert advisory panel

  • Charlotte Yeh, MD, AARP Services, Inc.
  • James Goodwin, PhD, Age UK
  • Elizabeth Ciemins, PhD, AMGA
  • William Burke, MD, Banner Alzheimer's Institute
  • Miranda Meunier, GNP, Billings Clinic
  • Patricia Coon, MD, Billings Clinic
  • Rhoda Au, PhD, Boston University
  • Shari Lang, MD, Centers for Medicare & Medicaid Services (CMS)
  • Ron Peterson, MD, PhD, Mayo Clinic
  • Martin McShane, MD, Optum International
  • Simon Lovestone, PhD, Oxford University
  • Rhonda Randall, DO, UnitedHealthcare, Retiree Solutions
  • Arun Karlamangla, MD, PhD, University of California, Los Angeles
  • Eleanor Perfetto, PhD, University of Maryland; National Health Council
[Configure Slider]

Related topics

*The Lewin Group. Baby boomers and Alzheimer’s disease: 28.4 million by 2050. Published Jan. 7, 2016. Accessed Sept. 27, 2017.